Karl Broich

11.6k total citations · 2 hit papers
119 papers, 3.5k citations indexed

About

Karl Broich is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Karl Broich has authored 119 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cellular and Molecular Neuroscience, 26 papers in Psychiatry and Mental health and 25 papers in Molecular Biology. Recurrent topics in Karl Broich's work include Neuroscience and Neuropharmacology Research (23 papers), Alzheimer's disease research and treatments (18 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Karl Broich is often cited by papers focused on Neuroscience and Neuropharmacology Research (23 papers), Alzheimer's disease research and treatments (18 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Karl Broich collaborates with scholars based in Germany, United States and Netherlands. Karl Broich's co-authors include Harald Hampel, Britta Haenisch, Klaus von Holt, Willy Gomm, Wolfgang Maier, Gabriele Doblhammer, Anne Fink, Frank Jessen, Kaj Blennow and Richard Frank and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Karl Broich

113 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

2010 469 citations Harald Hampel, Richard Frank et al. profile →
Association of Proton Pump Inhibitors With Risk of Dementia

2016 393 citations Willy Gomm, Karl Broich et al. profile →

Peers

Countries citing papers authored by Karl Broich

Since Specialization

Citations

This map shows the geographic impact of Karl Broich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Broich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Broich more than expected).

Fields of papers citing papers by Karl Broich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Broich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Broich. The network helps show where Karl Broich may publish in the future.

Co-authorship network of co-authors of Karl Broich

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Broich. A scholar is included among the top collaborators of Karl Broich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Broich. Karl Broich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Demenzen: Änderungen von ICD‑10 zu ICD-11 2025 ·Der Nervenarzt ·(unknown), Karl Broich	0
2	Clinical Evidence 2030 2025 ·Clinical Pharmacology & Therapeutics ·Peter Arlett, (unknown), Patrice Verpillat, Paolo Foggi, Ulla Liminga, Bruno Sepodes, (unknown), (unknown), Spiros Vamvakas, Kit C. B. Roes, Frank Pétavy, Steffen Thirstrup, María Jesús Lamas, Emer Cooke, Karl Broich	5
3	Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal Health 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Peter Arlett, Kit C. B. Roes, Flora T. Musuamba, Gabriel Westman, (unknown), (unknown), (unknown), Iftekhar Khan, (unknown), Karl Broich, Emer Cooke	2
4	Aufbau des neuen „Forschungsdatenzentrums Gesundheit“ zur Datenbereitstellung für die Wissenschaft 2024 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·(unknown), (unknown), Steffen Heß, Karl Broich	0
5	Cannabisarzneimittel in der Schmerztherapie : Zwischenauswertung der Cannabisbegleiterhebung hinsichtlich der primär behandelten Symptomatik Schmerz. 2019 ·Der Schmerz ·(unknown), Gabriele Schmidt‐Wolf, Karl Broich	2
6	Cav3.2 T-Type Calcium Channels Are Physiologically Mandatory for the Auditory System 2019 ·Neuroscience ·(unknown), Robin Seidel, (unknown), (unknown), Ralf Müller, (unknown), (unknown), Dan Ehninger, Jürgen Hescheler, Agapios Sachinidis, Karl Broich, (unknown), Anna Papazoglou, Marco Weiergräber	11
7	Hyperuricemia and dementia – a case-control study 2018 ·BMC Neurology ·(unknown), Willy Gomm, Karl Broich, Wolfgang Maier, Klaus Weckbecker, Britta Haenisch	19
8	Drug Regulation and Pricing — Can Regulators Influence Affordability? 2016 ·New England Journal of Medicine ·Hans‐Georg Eichler, (unknown), Karl Broich, Guido Rasi	35
9	PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE 2016 ·The Journal of Prevention of Alzheimer s Disease ·Harald Hampel, Sid E. O’Bryant, Juan I. Castrillo, Craig Ritchie, Katrine Rojkova, Karl Broich, Norbert Benda, Robert Nisticò, Richard Frank, Bruno Dubois, Valentina Escott‐Price, Simone Lista	78
10	Zusammenspiel zwischen Zulassung und Nutzenbewertung von Arzneimitteln 2015 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·(unknown), Jan Müller‐Berghaus, Thomas Sudhop, S. Vieths, Karl Broich	3
11	Medizinprodukte 2014 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·Wolfgang Lauer, (unknown), Allen Brinker, Karl Broich	3
12	Biomarkers for Alzheimer's disease therapeutic trials 2010 ·Progress in Neurobiology ·Harald Hampel, Gordon Wilcock, Sandrine Andrieu, Paul Aisen, Kaj Blennow, Karl Broich, María C. Carrillo, Nick C. Fox, Giovanni B. Frisoni, Maria Isaac, Simon Lovestone, Agneta Nordberg, David Prvulovic, Christina Sampaio, Philip Scheltens, Michael W. Weiner, Bengt Winblad, Nicola Coley, Bruno Vellas	100
13	Anticholinergic drug use and risk for dementia: target for dementia prevention 2010 ·European Archives of Psychiatry and Clinical Neuroscience ·Frank Jessen, Hanna Kaduszkiewicz, (unknown), Horst Bickel, Michael Pentzek, Steffi G. Riedel‐Heller, Michael Wagner, Siegfried Weyerer, Birgitt Wiese, Hendrik van den Bussche, Karl Broich, Wolfgang Maier	87
14	Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants 2009 ·European Neuropsychopharmacology ·Karl Broich	35
15	Biological markers for early detection and pharmacological treatment of Alzheimer's disease 2009 ·Dialogues in Clinical Neuroscience ·Harald Hampel, Karl Broich, (unknown), Johannes Pantel	30
16	Principle standards and problems regarding proof of efficacy in clinical psychopharmacology 2009 ·European Archives of Psychiatry and Clinical Neuroscience ·Hans‐Jürgen Möller, Karl Broich	18
17	Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: An exploratory approach 2005 ·Psychiatry Research Neuroimaging ·Astrid Zobel, Alexius Joe, Nikolaus Freymann, Hans Clusmann, Johannes Schramm, Michaël Reinhardt, Hans‐Jürgen Biersack, Wolfgang Maier, Karl Broich	86
18	Electroencephalogram alterations during treatment with olanzapine 2000 ·Psychopharmacology ·Frank Pillmann, (unknown), Karl Broich, Andreas Marneros	20
19	D₂-Dopamine Receptor Occupancy measured by IBZM-SPECT in Relation to Extrapyramidal Side Effects 1998 ·Pharmacopsychiatry ·Karl Broich, F. Grünwald, Siegfried Kasper, E. Klemm, H.-J. Biersack, H.‐J. Möller	15
20	Hemodilution in cerebral infarcts. 1991 ·PubMed ·A. Hartmann, (unknown), Christian Dettmers, Yasuyuki Tsuda, H. L. Lagrèze, Karl Broich	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact